ADA – New Lantus enlivens Sanofi diabetes strategy

Date June 25, 2013

In the race to launch a better long-acting insulin, Sanofi has the upper hand again. News that its new formulation of Lantus has proved equal to the existing product at controlling blood sugar whilst reducing the frequency of nighttime hypoglycaemia events should go a long way towards protecting the French group’s biggest seller from the twin threats of patent expiry and competition.

With US regulators having sent back Novo Nordisk’s Tresiba for four more years of work, and Lilly’s novel pegylated insulin sending some worrying liver toxicity signals, the chief emerging threat seems to be Lilly’s Lantus biosimilar. A new formulation with better outcomes and with new intellectual property protection should allow the French group to hold on to market share when the original formulation goes off patent in 2015.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd